Profil bibliographique

Koji Tamada

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

237Publications signalées

22594Citations signalées

4Affiliations récentes

Institutions déclarées

Yamaguchi University Yamanashi Research Institute SDS Biotech (Japan)Yamaguchi University Hospital

Domaines associés

Immunotherapy and Immune ResponsesCAR-T cell therapy researchImmune Cell Function and InteractionCancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Publications récentes

Accès ouvert 2026 articleOpenAlex

Autologous Glypican-3–Targeted, Armored CAR T Cells in Patients with Advanced Solid Tumors: A Phase 1 Dose-Escalation Study of TAK-102

Yasutoshi Kuboki, Takafumi Koyama, Masafumi Ikeda, Tomoyuki Satake et autres

0 citationsCancer Immunology Research

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure 4 from Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in Patients with Locally Advanced NSCLC

Atsuto Mouri, Hirotsugu Kenmotsu, Hiroshi Kagamu, Koichi Azuma et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure 2 from Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in Patients with Locally Advanced NSCLC

Atsuto Mouri, Hirotsugu Kenmotsu, Hiroshi Kagamu, Koichi Azuma et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure 3 from Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in Patients with Locally Advanced NSCLC

Atsuto Mouri, Hirotsugu Kenmotsu, Hiroshi Kagamu, Koichi Azuma et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure 1 from Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in Patients with Locally Advanced NSCLC

Atsuto Mouri, Hirotsugu Kenmotsu, Hiroshi Kagamu, Koichi Azuma et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure 6 from Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in Patients with Locally Advanced NSCLC

Atsuto Mouri, Hirotsugu Kenmotsu, Hiroshi Kagamu, Koichi Azuma et autres

0 citations

Accès ouvert 2026 otherOpenAlex

Data from Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in Patients with Locally Advanced NSCLC

Atsuto Mouri, Hirotsugu Kenmotsu, Hiroshi Kagamu, Koichi Azuma et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure 5 from Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in Patients with Locally Advanced NSCLC

Atsuto Mouri, Hirotsugu Kenmotsu, Hiroshi Kagamu, Koichi Azuma et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Table 1 from Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in Patients with Locally Advanced NSCLC

Atsuto Mouri, Hirotsugu Kenmotsu, Hiroshi Kagamu, Koichi Azuma et autres

0 citations

Accès ouvert 2026 articleOpenAlex

Gene expression profiling of recipient immune cells induced by 7 × 19 CAR-T cell dosing in a syngeneic mouse model

Yo Muraki, Yuumi Okuzono, Rina Kurisu, Akiko Abiru et autres

0 citationsPLoS ONE

2026 articleOpenAlex

Short-term Manufacturing of IL-7/CCL19-Expressing CAR T Cells Enhances and Prolongs Therapeutic Effects in Solid Tumor Models

Kohei Sakai, Yukimi Sakoda, Keishi Adachi, Yasuharu Ohta et autres

0 citationsMolecular Cancer Therapeutics

Accès ouvert 2026 articleOpenAlex

Efficient gene disruption with CRISPR–Cas3 in human T cells

Tomoaki Fujii, Yukimi Sakoda, Kazuto Yoshimi, Kohei Takeshita et autres

0 citationsNAR Cancer

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.